Stocktwits on MSN3d
BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement Builds
BridgeBio Pharma Inc. ($BBIO) stock surged 28% on Monday morning, hitting highs last seen in mid-September, after the company ...
Zacks.com on MSN2d
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
BridgeBio Pharma, Inc. BBIO recently announced that it obtained FDA approval for its pipeline candidate acoramidis for the ...
44,623 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Purchased by Intech Investment Management LLC
Intech Investment Management LLC acquired a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the 3rd ...
Research Analysts Set Expectations for BBIO FY2027 Earnings
Equities research analysts at Leerink Partnrs cut their FY2027 EPS estimates for shares of BridgeBio Pharma in a research ...
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM ...
BridgeBio Pharma (BBIO) Receives a Hold from Oppenheimer
Oppenheimer analyst Trevor Allred maintained a Hold rating on BridgeBio Pharma (BBIO – Research Report) today. The company’s shares opened ...
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM open-label extension (OLE) ...
Seeking Alpha4d
BBIO BridgeBio Pharma, Inc.
View BridgeBio Pharma, Inc. (BBIO) current and estimated P/E ratio data provided by Seeking Alpha.
Morningstar7d
BridgeBio Pharma Inc BBIO
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...